Molly Henderson Sells 1,291 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 1,291 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $8.00, for a total transaction of $10,328.00. Following the transaction, the chief financial officer now directly owns 98,156 shares in the company, valued at $785,248. The trade was a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Phathom Pharmaceuticals Stock Down 4.7 %

PHAT opened at $7.45 on Monday. The company’s 50-day moving average price is $12.11 and its 200 day moving average price is $13.09. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $6.07 and a fifty-two week high of $19.71. The firm has a market cap of $509.41 million, a price-to-earnings ratio of -1.31 and a beta of 0.56.

Analyst Ratings Changes

A number of research firms have commented on PHAT. HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Wednesday, December 11th.

Institutional Trading of Phathom Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Huntington National Bank boosted its position in Phathom Pharmaceuticals by 62.2% during the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock valued at $27,000 after purchasing an additional 564 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Phathom Pharmaceuticals by 41.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock valued at $43,000 after acquiring an additional 722 shares during the period. US Bancorp DE grew its position in shares of Phathom Pharmaceuticals by 28.6% during the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after acquiring an additional 1,166 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Phathom Pharmaceuticals by 10.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after acquiring an additional 1,339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Phathom Pharmaceuticals by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company’s stock valued at $104,000 after purchasing an additional 2,987 shares during the last quarter. 99.01% of the stock is currently owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.